Equity Brief · Healthcare2026-05-20
ABT·Healthcare

Abbott Laboratories

I · KI-Analyse

Kurzfassung

Abbott makes and sells healthcare products worldwide across four main areas: generic pharmaceuticals for chronic conditions, laboratory diagnostic systems and rapid tests, infant formula and nutritional products for children and adults, and medical devices including heart valves, glucose monitors, and pacemakers [Yahoo Finance]. The company serves hospitals, clinics, pharmacies, and consumers in both developed and emerging markets.

Abbott Laboratories is a diversified healthcare giant operating across four major segments: established pharmaceuticals, diagnostic products, nutritional products, and medical devices [Yahoo Finance]. The company generates $44.3B in annual revenue with strong margins and minimal debt, earning a perfect 10.0/10 financial health score [Yahoo Finance]. Recent strategic moves include a $21B acquisition of cancer diagnostics firm Exact Sciences and a pivot toward volume-driven nutrition sales, though the nutrition division contracted 6% in early 2026 [Yahoo Finance].

Abbott maintains exceptionally strong financial health with minimal debt, robust cash generation, and consistent profitability.

Kurzfassung AI analysisKonfidenz 8/10

Sentinellis-Score

10/10

Financially healthy

Marktkapitalisierung

$154.7B

Umsatz (12 Monate)

$44.3B

II · Aktuelle Nachrichten

Was den Kurs bewegt hat

6 stories · ranked by relevance

  • macro2026-05-20

    Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum

    Yahoo Finance

  • macro2026-05-18

    ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

    Yahoo Finance

  • macro2026-05-19

    Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings

    Yahoo Finance

  • macro2026-05-18

    Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

    Yahoo Finance

  • macro2026-05-18

    Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion

    Yahoo Finance

  • macro2026-05-18

    Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo

    Yahoo Finance

Premium · kostenlos mit jedem Konto

The nutrition division shrank 6% in early 2026 due to price increases that backfired by reducing customer purchases, loss of a major U.S. government contract for low-income family nutrition products, and persistently high raw material costs since the pandemic [Yahoo Finance]

1 von 4 Risiken in diesem Bericht

Risiken

4

Chancen

6

Warnsignale

2

Führung

10

21 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.

Vollständige Abbott Laboratories-Analyse freischalten

Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.

  • 4 Risiken, 6 Chancen und 2 Warnsignale — jeweils mit Quelle
  • Über 100 Finanzkennzahlen mit Charts und Vergleichen
  • Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
  • Führungsteam und Vergütung
  • PDF-Export für offline
Alle 12 Erkenntnisse freischalten3 kostenlose Berichte · keine Karte

III · Ähnliche Unternehmen

Das könnte Sie auch interessieren

Same sector · Healthcare or comparable health

Auf Ihre Watchlist setzen?

Read three companies free. Keine Karte.

3 kostenlose Berichte sichern